Pfizer offers 6.5% dividend yield with promising drug pipeline despite patent risks.

Pfizer shares currently yield 6.5%, attracting investors despite challenges from patent expiries and lukewarm revenue guidance. The company is investing heavily in innovative treatments, especially in oncology, aiming for $10 billion in oncology revenue by 2030, and has a promising Lyme disease vaccine in development. While Pfizer’s stock has underperformed and faces risks, its diverse pipeline and low market correlation make it a compelling long-term value and income play for patient investors.